{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:59:32Z","timestamp":1781027972697,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Science Center","award":["2015\/17\/B\/NZ7\/02984"],"award-info":[{"award-number":["2015\/17\/B\/NZ7\/02984"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.pbb.2018.06.003","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T19:31:23Z","timestamp":1529350283000},"page":"50-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Neurochemical changes underlying schizophrenia-related behavior in a modified forced swim test in mice"],"prefix":"10.1016","volume":"172","author":[{"given":"Monika","family":"Wo\u017aniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Cie\u015blik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Marciniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Lenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4045-0597","authenticated-orcid":false,"given":"Andrzej","family":"Pilc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Wieronska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.pbb.2018.06.003_bb0005","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1523\/JNEUROSCI.2721-09.2010","article-title":"Dopamine and memory: modulation of the persistence of memory for novel hippocampal NMDA receptor-dependent paired associates","volume":"30","author":"Bethus","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2018.06.003_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.010909.105705","article-title":"2010. GPCR interacting proteins (GIPs) in the nervous system: roles in physiology and pathologies","volume":"50","author":"Bockaert","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.pbb.2018.06.003_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tips.2008.10.006","article-title":"Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia","volume":"30","author":"Conn","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.pbb.2018.06.003_bb0020","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0026-895X(25)11082-1","article-title":"Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase","volume":"39","author":"Cornfield","year":"1991","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2018.06.003_bb0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jnr.20122","article-title":"GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia","volume":"76","author":"Dracheva","year":"2004","journal-title":"J. Neurosci. Res."},{"issue":"2\u20133","key":"10.1016\/j.pbb.2018.06.003_bb0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.schres.2004.02.017","article-title":"GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67\u202fkDa and Reelin proteins in cerebellum","volume":"72","author":"Fatemi","year":"2005","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.pbb.2018.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1734-1140(09)70166-5","article-title":"Effects of GABAB receptor agonists on cocaine hyperlocomotor and sensitizing effects in rats","volume":"61","author":"Frankowska","year":"2009","journal-title":"Pharmacol. Rep."},{"issue":"17","key":"10.1016\/j.pbb.2018.06.003_bb0045","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/jm00017a015","article-title":"Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists","volume":"38","author":"Froestl","year":"1995","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.pbb.2018.06.003_bb0050","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.pbb.2011.06.029","article-title":"Positive allosteric modulators at GABAB receptors exert intrinsic actions and enhance the influence of baclofen on light-induced phase shifts of hamster circadian activity rhythms","volume":"99","author":"Gannon","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"1\u20132","key":"10.1016\/j.pbb.2018.06.003_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-8993(94)90512-6","article-title":"Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study","volume":"668","author":"Gasbarri","year":"1994","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.pbb.2018.06.003_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0278-5846(96)00157-1","article-title":"The dopaminergic mesencephalic projections to the hippocampal formation in the rat","volume":"21","author":"Gasbarri","year":"1997","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.pbb.2018.06.003_bb0065","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.psychres.2005.09.010","article-title":"Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder","volume":"143","author":"Gray","year":"2006","journal-title":"Psychiatry Res."},{"issue":"11","key":"10.1016\/j.pbb.2018.06.003_bb0070","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archpsyc.57.11.1061","article-title":"Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study","volume":"57","author":"Guidotti","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.pbb.2018.06.003_bb0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0006-3223(97)00321-1","article-title":"Alterations in the cortical serotonergic system in schizophrenia: a postmortem study","volume":"42","author":"Gurevich","year":"1997","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2018.06.003_bb0080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/schbul\/8.3.438","article-title":"The dopamine hypothesis - an overview of studies with schizophrenia-patients","volume":"8","author":"Haracz","year":"1982","journal-title":"Schizophr. Bull."},{"issue":"1 Suppl","key":"10.1016\/j.pbb.2018.06.003_bb0085","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/BF02245005","article-title":"Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia","volume":"112","author":"Hashimoto","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2018.06.003_bb0090","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/schbul\/sbq031","article-title":"Dopaminergic dysfunction in schizophrenia: salience attribution revisited","volume":"36","author":"Heinz","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.pbb.2018.06.003_bb0095","first-page":"12","article-title":"Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia","volume":"9","author":"Javitt","year":"1987","journal-title":"Hillside J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.pbb.2018.06.003_bb0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00213-011-2567-y","article-title":"Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test","volume":"221","author":"Langen","year":"2012","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2018.06.003_bb0105","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"4","key":"10.1016\/j.pbb.2018.06.003_bb0110","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/bjp.2008.135","article-title":"Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors","volume":"154","author":"Malherbe","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2018.06.003_bb1000","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1196\/annals.1300.065","article-title":"Glutamatergic animal models of schizophrenia","volume":"1003","author":"Moghaddam","year":"2003","journal-title":"Ann N YAcad Sci"},{"key":"10.1016\/j.pbb.2018.06.003_bb0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/j.1600-0447.1955.tb01014.x","article-title":"Chlorpromazine (\u201cLargactil\u201d) in the Management of Psychotic Patients","volume":"30","author":"Munch-Petersen","year":"1955","journal-title":"Acta Psychiatr. Neurol. Scand."},{"issue":"5","key":"10.1016\/j.pbb.2018.06.003_bb0125","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1476-5381.1995.tb15106.x","article-title":"Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia","volume":"116","author":"Noda","year":"1995","journal-title":"Br. J. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.pbb.2018.06.003_bb0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(97)00067-8","article-title":"Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice","volume":"324","author":"Noda","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2018.06.003_bb0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0893-133X(00)00138-X","article-title":"Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions","volume":"23","author":"Noda","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pbb.2018.06.003_bb0140","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neuropharm.2009.01.004","article-title":"Effects of antipsychotic drugs on MK-801-induced attentional and motivational deficits in rats","volume":"56","author":"Paine","year":"2009","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2018.06.003_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001756-200101220-00010","article-title":"Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment","volume":"12","author":"Qiao","year":"2001","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.pbb.2018.06.003_bb0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiat."},{"issue":"1\u20132","key":"10.1016\/j.pbb.2018.06.003_bb0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0006-8993(95)01361-X","article-title":"Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia","volume":"708","author":"Sumiyoshi","year":"1996","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.pbb.2018.06.003_bb0160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1503\/jpn.100048","article-title":"Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders","volume":"36","author":"Thompson","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2018.06.003_bb0165","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00221-002-1259-6","article-title":"Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat hippocampus","volume":"147","author":"Tokarski","year":"2002","journal-title":"Exp. Brain Res."},{"issue":"3","key":"10.1016\/j.pbb.2018.06.003_bb0170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.biopsych.2004.10.019","article-title":"Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains","volume":"57","author":"Torrey","year":"2005","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pbb.2018.06.003_bb0175","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/j.1476-5381.2011.01301.x","article-title":"The GABAB receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice","volume":"163","author":"Wiero\u0144ska","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2018.06.003_bb0180","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbr.2013.08.007","article-title":"The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by mGlu2\/3 receptor agonist, LY379268, in 5-HT1A dependent","volume":"256","author":"Wiero\u0144ska","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.pbb.2018.06.003_bb0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00213-014-3657-4","article-title":"The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies","volume":"232","author":"Wiero\u0144ska","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2018.06.003_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuint.2015.03.010","article-title":"mGlu5-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia","volume":"88","author":"Wiero\u0144ska","year":"2015","journal-title":"Neurochem. Int."},{"issue":"5","key":"10.1016\/j.pbb.2018.06.003_bb0195","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1570159X13666150516000630","article-title":"Involvement of GABAB receptor signaling in antipsychotic-like action of the novel orthosteric agonist of the mGlu4 receptor, LSP4-2022","volume":"14","author":"Wo\u017aniak","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.pbb.2018.06.003_bb0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuropharm.2016.06.025","article-title":"Neurochemical and behavioral studies on the 5-HT1A-dependent antipsychotic action of the mGlu4 receptor agonist LSP4-2022","volume":"115","author":"Wo\u017aniak","year":"2017","journal-title":"Neuropharmacology"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305718301059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305718301059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:33:56Z","timestamp":1758774836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305718301059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":39,"alternative-id":["S0091305718301059"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2018.06.003","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurochemical changes underlying schizophrenia-related behavior in a modified forced swim test in mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2018.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}